Silvia Nicolini
Meldola, 47014, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 29 publications
Choline PET/CT in the PSMA Era: Clinical Repositioning, Biological Perspectives, and Emerging Applications.
Journal: Diagnostics (Basel, Switzerland)
Published: June 03, 2026
Radioligand therapy for primary brain tumors: a PRISMA-based systematic review of meningiomas and gliomas.
Journal: Frontiers in medicine
Published: October 20, 2025
PSMA for HCC: a new frontier in precision medicine for liver cancer?
Journal: Cancer treatment and research communications
Published: October 06, 2025
Efficacy, toxicity, and clinical outcomes of 177Lu-PSMA-617 radioligand therapy at 5.5 GBq per cycle in patients with advanced castration-resistant prostate cancer: a prospective, single arm, phase II study.
Journal: European journal of nuclear medicine and molecular imaging
Published: July 14, 2025
Lu-PRRT Used More Intensively on Advanced Gastro-Entero-Pancreatic and Lung Neuroendocrine Neoplasms: Preliminary Results on Toxicity from a Randomized Study.
Journal: Neuroendocrinology
Published: June 12, 2024
Peptide Receptor Radionuclide Therapy in Advanced Refractory Meningiomas: Efficacy and Toxicity in a Long Follow-up.
Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Published: November 27, 2023
177Lu-DOTATATE Efficacy and Safety in Functioning Neuroendocrine Tumors: A Joint Analysis of Phase II Prospective Clinical Trials.
Journal: Cancers
Published: September 11, 2022
Theragnostic in neuroendocrine tumors.
Journal: The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of...
Published: December 09, 2021
Circulating androgen receptor gene amplification and resistance to 177Lu-PSMA-617 in metastatic castration-resistant prostate cancer: results of a Phase 2 trial.
Journal: British journal of cancer
Published: February 04, 2021
Combined use of 177Lu-DOTATATE and metronomic capecitabine (Lu-X) in FDG-positive gastro-entero-pancreatic neuroendocrine tumors.
Journal: European journal of nuclear medicine and molecular imaging
Published: November 09, 2020
A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy (PRRT): 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods.
Journal: Journal of visualized experiments : JoVE
Published: May 12, 2020
Last Updated: 09/26/2026